Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow CUE
Cue Biopharma, Inc. (CUE) EV/Sales
As of 16 October 2026, Cue Biopharma, Inc. (CUE) trades at a EV/Sales of 2.4×. Over the past ten years it has ranged from −0.2× (March 2026) to 377× (May 2023); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.1× | (98.23%) |
| FY2024 | 4.7× | (70.17%) |
| FY2023 | 15.7× | (31.08%) |
| FY2022 | 22.8× | 14.09% |
| FY2021 | 20.0× | (77.51%) |
| FY2020 | 89.0× | 4.02% |
| FY2019 | 85.6× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.9× | 822.02% |
| Mar 2026 | 0.5× | 538.99% |
| Dec 2025 | 0.1× | (98.90%) |
| Sep 2025 | 7.6× | 57.63% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| CUE Cue Biopharma, Inc. | 2.4× |
| KRRO Korro Bio, Inc. compare | 8.4× |
| ALXO ALX Oncology Holdings Inc. compare | 8.4× |
| MOLN Molecular Partners AG Sponsored ADR compare | 9.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)